Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.98 |
| ▸ | CA12 | O43570 | 2/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.98 |
| ▸ | CA1 | P00915 | 2/20 | 0.98 |
| ▸ | CA2 | P00918 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | MAOA | P21397 | 2/20 | 0.98 |
| ▸ | CA4 | P22748 | 2/20 | 0.98 |
| ▸ | CA6 | P23280 | 2/20 | 0.98 |
| ▸ | CA5A | P35218 | 2/20 | 0.98 |
| ▸ | CA7 | P43166 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.98 |
| ▸ | CA9 | Q16790 | 2/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.98 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL458654 | 0.99 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL973 | 0.99 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL29384901 | 0.99 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL39237 | 0.99 | HRH2 (1.00) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28032679 | 0.98 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863201 | 0.98 | HRH2 (0.98) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL1863206 | 0.97 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL7119657 | 0.97 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL28528271 | 0.97 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 | |
| Famotidine SCHEMBL9817308 | 0.97 | HRH2 (0.95) | HRH2SLC22A2CA12SLC22A3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124475-B2 | Hydrogen sulfide donor in organic salt form and preparation method therefor | CHENGDU KAOENSI SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2021-09-21 | — | — | US | disclosed |
| US-20200199067-A1 | HYDROGEN SULFIDE DONOR IN ORGANIC SALT FORM AND PREPARATION METHOD THEREFOR | CHENGDU KAOENSI SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124475-B2 | Hydrogen sulfide donor in organic salt form and preparation method therefor | TST, STS, HDHD5 | HRH2 1565/4885SLC22A2 1746/4885CA12 1155/4885 |
| US-20200199067-A1 | HYDROGEN SULFIDE DONOR IN ORGANIC SALT FORM AND PREPARATION METHOD THEREFOR | TST, STS, HDHD5 | HRH2 1565/4885SLC22A2 1746/4885CA12 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.